中国抗体-B(03681.HK) 宣布,其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开放研究》上发表。该研究显示,SM17通过双重抑制Th2/Th17通路及抗纤维化活性,显著改善慢性鼻窦炎伴鼻息肉(CRSwNP)和特发性肺纤维化(IPF)的病理特征,支援其成为变革性疗法的潜力。 SM17通过阻断IL-25/IL-17RB信号通路发挥作用。研究表明,IL-25是驱动...
Source Link中国抗体-B(03681.HK) 宣布,其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开放研究》上发表。该研究显示,SM17通过双重抑制Th2/Th17通路及抗纤维化活性,显著改善慢性鼻窦炎伴鼻息肉(CRSwNP)和特发性肺纤维化(IPF)的病理特征,支援其成为变革性疗法的潜力。 SM17通过阻断IL-25/IL-17RB信号通路发挥作用。研究表明,IL-25是驱动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.